Cellectis (NASDAQ:CLLS) Announces Quarterly Earnings Results

Cellectis (NASDAQ:CLLS) released its earnings results on Thursday. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.22), Zacks reports. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. The firm had revenue of $33.22 million during the quarter, compared to analyst estimates of $5.90 million.

Cellectis Stock Performance

Shares of Cellectis stock opened at $1.24 on Friday. The business has a 50-day simple moving average of $1.53 and a 200-day simple moving average of $1.83. The company has a market cap of $68.92 million, a PE ratio of -0.95 and a beta of 3.27. Cellectis has a one year low of $1.14 and a one year high of $3.38. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on Cellectis in a research report on Thursday, February 27th. They set a “buy” rating for the company.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.